Society of Gynecologic Oncologists 39th Annual Meeting on Women's Cancer to Include Sessions on HPV and Cervi...( Eight Sessions to be Dedicated to...),Health

Eight Sessions to be Dedicated to the Prevention and Treatment of Cervical Cancer and HPV's Related Correlation to the Disease

CHICAGO, March 10 /PRNewswire-USNewswire/ -- It has been almost two years since the first vaccine to prevent cervical cancer was approved for regular clinical use, and the Society of Gynecologic Oncologists (SGO), the professional association for experts in women's cancer, will take a critical look at HPV and Cervical Cancer as well as the vaccine, its impact, and its future during the 2008 Annual Meeting on Women's Cancer, March 9 - 12, 2008, in Tampa, Florida.

Due to their background in obstetrics and gynecology - and specialized training in oncology, surgery, chemotherapy, radiation therapy and supportive care - gynecologic oncologists have the best understanding of cervical cancer, how it affects women, and how it can best be prevented. "At the Annual Meeting on Women's Cancer, no less than eight sessions have been built around varying aspects of this disease," explains SGO President, Andrew Berchuck, MD. "Of these, six specifically address the quadrivalent and bivalent vaccines that currently exist to prevent cervical cancer. We hope, by putting the spotlight on cervical cancer at this meeting, we can continue to extend and expand the knowledge about its prevention and treatability beyond the medical community to the general public in the hopes of reducing and even eliminating its existence."

The data presented during the meeting provides an array of new information on the vaccine and the human papillomavirus (HPV) - specifically HPV types 16 and 18, which cause 70 percent of all cervical cancers. For the gynecologic oncologists participating in SGO's Annual Meeting, these presentations and research will provide a first-look at some of the data emerging from preliminary studies on the long-term side effects of the vaccines, alternative benefits of vaccination, and genetic susceptibility to HPV. One such
'/>"/>